west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "YAN Lünan" 24 results
  • Strategies for diagnosis and treatment of hepatocellular carcinoma

    In recent years, the diagnosis and treatment of hepatocellular carcinoma (HCC) has entered a brand-new era due to the advancement of diagnosis methods and the emergence of targeted drugs and immunotherapy drugs. The author described and summarized in detail the screening program, diagnostic thought and procedure, clinical staging, mechanism of targeted and immune therapy and application range of HCC.

    Release date: Export PDF Favorites Scan
  • Fighting for further long-term survival rate after liver transplantation in China

    Collect the 15 patients with orthotopic liver transplantation (OLT) in the West China Hospital of Sichuan University from February 1999 to December 2002. The patients were confirmed that had healthy survival more than 20 years. The factors affecting the long-term survival were summarized and summed up the favorable factors that promoted greatly increasing of liver transplantation effect in recent years, in order to further improve the long-term survival rate of patients underwent liver transplantation.

    Release date: Export PDF Favorites Scan
  • Pay attention to the clinical value and significance of S9 segment of liver

    Couinaud first proposed the naming of S9 segment of liver in 1994, and Liu Yunyi further promoted this naming in his work “Applied Anatomy of Hepatectomy and Liver Transplantation” in 2016. However, it has not been widely recognized and supported in the field of liver surgery for a long time. In recent years, due to the promotion and gradual maturity of endoscopic technology, there has been a more detailed understanding and demand for anatomy of liver and bile duct. Therefore, this article further explores the clinical value and significance of S9 segment of liver.

    Release date: Export PDF Favorites Scan
  • Venous thromboembolism prophylaxis after hepatectomy

    Objective To investigate the risk factors and prevention methods of the venous thromboembolism (VTE) after hepatectomy. Methods The literatures about VTE after hepatectomy in recent years at home and abroad were reviewed and summarized. Results The risk factors for postoperative VTE include tumor, male, old age, massive hepatectomy, hypercoagulability, etc. The incidence of VTE in patients with massive hepatectomy is significantly higher, which is closely related to the hypercoagulability caused by postoperative liver dysfunction. Effective prophylaxis include mechanical methods and anticoagulant drugs, the latter of which can markedly reduce the incidence of VTE. For patients who develop postoperative liver insufficiency, including those with cirrhosis and high risk of bleeding, anticoagulant VTE prophylaxis dosing decisions should be made with caution. In addition, it is rationale for extended thromboprophylaxis in high risk patients. Conclusions VTE is a common complication after hepatectomy, resulting in prolonged postoperative hospital stay and increased postoperative mortality. Therefore, it is important to determine the risk of VTE after surgery to improve the prognosis of patients after hepatectomy.

    Release date:2017-07-12 02:01 Export PDF Favorites Scan
  • Application of artificial intelligence in diagnosis and treatment of liver cancer

    ObjectiveTo better understand artificial intelligence (AI) and its application in management of liver cancer.MethodThe relevant literatures about AI in the diagnosis and treatment of liver cancer in recent years were reviewed.ResultsIn terms of diagnosis, the deep learning could precisely and quickly complete the imaging localization and segmentation of the liver, which was helpful for the diagnosis, while radiomics had a high value in assisting the diagnosis of liver cancer, predicting the postoperative recurrence and long-term survival of patients with liver cancer. In regard of treatment, although it was still difficult for AI to intervene in liver surgery, it had significant advantages in formulating individualized operation scheme for patients with liver cancer, which enabled precise hepatectomy and was helpful for prediction of intraoperative bleeding. AI fusion imaging could provide assistance in operation plan making and realize the precise placement of ablation needle. AI was able to predict the tumor response or even tumor progression after interventional therapy and radiotherapy. Pathological analysis was also facilitated by AI and was able to identify some details and feature textures that were difficult to manually distinguish. For transplantation, guidance of AI on the allocation of donor livers based on hazards models helped make better use of limited organ resources. AI could be applied in prognosis prediction in almost all treatment modalities.ConclusionsAI provides more efficient and precise diagnosis, treatment support and prognosis than conventional medical process in liver cancer, generally by constructing a fully functional model based on a series of data mining methods combined with statistical analysis.

    Release date:2020-09-23 05:27 Export PDF Favorites Scan
  • Interpretation of “Chinese Guideline for Diagnosis and Treatment of Primary Liver Cancer (version-2022)” and “BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 update”

    “Chinese Guideline for Diagnosis and Treatment of Primary Liver Cancer (version-2022)” (China Liver Cancer Staging, Abbreviation “CNLC 2022”) was updated recently and the “Barcelona Clinical Liver Cancer Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 update” (Abbreviation “BCLC 2022”) was also updated in December 2021. The similarities and differences of the two guidelines were interpreted. For the BCLC stage B and C, which are equivalent to CNLC stage Ⅱa and Ⅱb and CNLC stage Ⅲa, respectively, the recommendation of surgical treatment and radiation therapy are disparate in the CNLC 2022 and BCLC 2022. For the systematic treatment of advanced liver cancer, Atezolizumab-Bevacizumab, Renvatinib and Sorafenib were both recommended as the first-line medication in the two guidelines. However, the CNLC 2022 is more flexible than BCLC 2022, which provides more treatment options for Chinese liver cancer patients. It is worth paying attention to two important new concepts proposed in the BCLC 2022: stage migration during treatment and untreatable progression. The BCLC stage B was divided into three subgroups according to tumor burden and liver function and different clinical pathways were recommended in the BCLC 2022.

    Release date: Export PDF Favorites Scan
  • A new surgical strategy for preventing large-for-size syndrome after DCD liver transplantation in adults

    Large-for-size syndrome (LFSS) is a fatal complication of abdominal and thoracic organ compression due to mismatch of the size of the graft and recipient abdominal cavity. In recent years, with the increased prevalence of obesity epidemic among the donor pool, the incidence of LFSS tends to increase in adult liver transplantation. However, it is still unclear how to effectively prevent LFSS after adult death after citizen death (DCD) liver transplantation. Almost all transplantation centers rely on experience to deal with it, and there is no objective prevention strategy. This article summarizes the current problems in preventing LFSS after adult DCD liver transplantation, and our team’s exploration of the existing problems.

    Release date: Export PDF Favorites Scan
  • A new classification of congenital biliary dilatation—HUAXI CBD classification

    ObjectiveTo intend to propose a new clinical classification of congenital biliary dilatation (CBD) which is more concise and suitable for diagnosis and treatment, and explore feasibility and reliability of the new classification. MethodsBased on the preoperative imaging data of patients with CBD admitted to the Department of Pediatric Surgery of West China Hospital of Sichuan University, from January 2015 to December 2018, a new classification of CBD was accomplished according to the site of bile duct dilatation lesions, which was named HUAXI CBD classification. The CBD was classified into 4 types: type Ⅰ (distal extra-hepatic bile duct dilatation), type Ⅱ (distal extra-hepatic combined with right and left primary hepatic bile duct dilatation), type Ⅲ (extra-hepatic combined with secondary and above hepatic bile duct dilatation), and type Ⅳ (intra-hepatic bile duct dilatation). Meanwhile, the feasibility and reliability of the HUAXI CBD classification were analyzed. ResultsA total of 300 patients with CBD were included in this study. According to the HUAXI CBD classification method, 240 cases were type Ⅰ, 48 cases were type Ⅱ, 10 cases were type Ⅲ, and 2 cases were type Ⅳ. For type Ⅰ, 236 patients underwent cholecystectomy and Roux-en-Y hepaticojejunostomy and 4 cases were treated non-operatively; For type Ⅱ, 48 patients underwent cholecystectomy, central hepatic duct reconstruction and Roux-en-Y hepaticojejunostomy; For type Ⅲ, 9 patients underwent cholecystectomy and Roux-en-Y hepaticojejunostomy, 5 of which had intrahepatic dilatation confined to part of the liver lobe and underwent partial hepatectomy with intra-hepaticojejunostomy. One case was treated with percutaneous transhepatic cholangial drainage (PTCD) only; two type Ⅳ patients were treated with PTCD only. Patients with type Ⅰ had a normal hepatobiliary function after surgery and a good prognosis; patients with type Ⅱ had good recovery of liver function in 37 cases (77.1%), but 11 cases (22.9%) had postoperative complications during follow-up; patients with type Ⅲ and Ⅳ had high incidence of cholangitis (6/10, 2/2, respectively) and choledocholithiasis (5/10, 2/2, respectively) after surgery, especially those with diffuse intrahepatic dilatation having a poor prognosis, eventually developing cirrhosis and necessitating liver transplantation. ConclusionThe HUAXI CBD classification is consistent with treatment principles, concise and easy to remember, and more suitable for pediatric clinical application, which can effectively assist in the selection of clinical treatment strategies for children with BD.

    Release date: Export PDF Favorites Scan
  • Reoperation of a patient with type Ⅳa congenital choledochal cyst

    Objective To explore surgery strategy of reoperation for type Ⅳa congenital choledochal cyst. Methods The patient was a 20-year-old female with repeated right upper abdominal pain and fever for more than 1 year and aggravation for more than 1 month, and the choledochal cyst excison was performed 15 years ago. The MRI revealed that a huge cyst located in the left lobe of liver, with multiple intrahepatic calculus. The patient was diagnosed with a type Ⅳa congenital choledochal cyst and choledochojejunostomy later and the intrahepatic dilated bile duct was untreated. Results The cystic dilatation of the intrahepatic bile duct was confirmed during the reoperation, and the multiple stones with pus formation were seen, the color of the right liver was normal and the anatomical left hemihepatectomy was performed. The original anastomosis had no stenosis then was preserved. An about 1.5 cm length of extrahepatic bile duct was dissociated from the upper of anastomosis, and the extrahepatic bile duct was cut open and explored with a choledochoscope. The T-tube drainage was performed following removing the stone. The patient recovered well and was discharged smoothly following the surgery. The cholangiography 6 weeks later revealed that the biliary tract was patency and there was no residual stone. There was no jaundice or fever afterwards. Conclusion Complete excision of choledochal cyst and hepaticoduodenostomy is widely accepted as a standard surgery for type Ⅳa congenital choledochal cyst.

    Release date:2018-09-11 11:11 Export PDF Favorites Scan
  • MDT discussion of a case of primary diffuse large B cell lymphoma of liver

    ObjectiveTo investigate the clinical manifestations, imaging manifestations, etiology, histological origin, pathological characteristics, diagnosis and differential diagnosis, selection of treatment methods, and prognosis of primary diffuse large B cell lymphoma of livers (PDLBCLL), so as to improve understanding and reasonable diagnosis and treatment of this kind of disease.MethodThe clinicopathologic data of a case of PDLBCLL diagnosed in the West China Hospital of Sichuan University in June 2019 were analyzed retrospectively.ResultsIt was very difficult to diagnose PDLBCLL preoperatively and to distinguish PDLBCLL from primary liver cancer and other liver space occupying lesions. It was also easy to ignore the possibility of invasion of liver by lymphopoietic tissue tumor, which was often diagnosed by postoperative pathological diagnosis or puncture biopsy, and after the elimination of hematological diseases by various examinations. This patient was admitted to the hospital as a space occupying in right liver. Preoperative imaging examination considered that may be a tumor. After MDT discussion, considering that the nature of the tumor should be confirmed by surgical resection, and then go to the Department of Oncology. Irregular right hemihepatectomy + cholecystectomy + hilar lymphadenectomy + diaphragmatic repair was performed after MDT discussion. The diagnosis of PDLBCLL was confirmed by postoperative pathological examination. The operation duration was about 230 min, and the intraoperative blood loss was about 200 mL. The patient recovered well without complications and was discharged on the 10th day after operation. The patient was followed up for 9 months. The liver and kidney function, electrolytes and abdominal Doppler ultrasound examination were regularly reviewed every month. No obvious abnormality was found in these results.ConclusionsAt present, there is no unified treatment principle, most of them will undergo surgery, chemotherapy, radiotherapy or combined treatment. Due to its unknown etiology and unclear mechanism, clinicians can only implement individualized treatment according to the characteristics of patients’ conditions.

    Release date:2021-02-08 07:10 Export PDF Favorites Scan
3 pages Previous 1 2 3 Next

Format

Content